Evaluation of the Safety of A Novel Anti-HER2 Immunotoxin Containing Modified Fragment of Exotoxin in BALB/C Mice.

BACKGROUND

Human epidermal growth factor-2 (HER-2) receptors are overexpressed in some malignancies like breast cancer. Previously, we constructed a novel anti-HER immunotoxin, scFv-PE35KDEL, containing modified fragments of exotoxin, which showed remarkable cytotoxicity against breast cancer cells. safety evaluation is essential for evaluating toxicity to perform efficacy studies. This study aimed to evaluate the acute toxicity of scFv-PE35KDEL in BALB/c mice.

OBJECTIVES

The objective of this research was to express and purify the recombinant scFv-PE35KDEL protein and remove its endotoxin content, as well as to evaluate its toxicity profile by determining the LD and monitoring body weight changes in BALB/c mice following injection.

MATERIALS AND METHODS

After expression and purification of scFv-PE35KDEL, BALB/c mice were intraperitoneally administered single doses of 250, 500, 1000, and 2000 µg.kg of immunotoxin. Mice's weight, body temperature, and acute toxicity symptoms were evaluated every odd day for two weeks. Histopathological evaluation of the kidney, liver and lungs was performed.

RESULTS

All mice died after a single dose of 2000 µg.kg of immunotoxin, but after exposure to 1000 µg.mg, all mice survived for 15 days. There was no significant difference in the body temperature between the groups ( > 0.05). There was a considerable weight loss at 500 and 1000 µg.kg doses until three days ( < 0.05) which recovered gradually. Diarrhea and loss of muscular tonicity were among the common adverse effects, which were worsened by increasing the dose to 1000 µg.mg. Based on histopathological analysis, no specific toxicity was observed in the liver and kidney tissues at doses up to 1000 µg.kg.

CONCLUSION

These findings revealed that the LD50 of scFv-PE35KDEL is in the range of 1000-2000 µg.mg and it seems to be a safe and non-toxic agent, and could be a promising candidate for anti-HER2 cancer therapy. However, further evaluations are required.